RC
CMPX icon

Rovin Capital’s Compass Therapeutics CMPX Stock Holding History

Rovin Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$72K Hold
13,495
– – 0.02% 193
2025
Q3 		$47K Hold
13,495
– – 0.01% 192
2025
Q2 		$35K Hold
13,495
– – 0.01% 185
2025
Q1 		$26K Hold
13,495
– – 0.01% 176
2024
Q4 		$20K Hold
13,495
– – 0.01% 161
2024
Q3 		$25K Buy
+13,495
New +$16.8K 0.01% 168

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rovin Capital's CMPX Position: Q4 2025 in Review

Rovin Capital held its Compass Therapeutics (CMPX) position steady in Q4 2025 at 13,495 shares worth $72K. The position accounts for 0.02% of the portfolio, ranked #193.

Rovin Capital first reported a position in CMPX in Q3 2024 and has held it in 6 quarters since. 173 funds tracked by Wall St. Rank hold CMPX as of Q4 2025.

  • Rovin Capital held 13,495 shares of Compass Therapeutics worth $72K as of Q4 2025.
  • Rovin Capital left its Compass Therapeutics share count unchanged in Q4 2025.
  • Compass Therapeutics made up 0.02% of Rovin Capital's portfolio in Q4 2025, its #193 holding.
  • Rovin Capital first reported a position in Compass Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 173 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2025.

Based on Rovin Capital's 13F filing for Q4 2025, filed 9 Feb 2026.